ESMO® 2025 Highlights: Presenter Vignette – Tony Mok
Tony Mok
BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO
The Chinese University of Hong Kong
LBA73
Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
